This invention is directed to an erythropoietin mutein having in vivo biological activity for causing bone marrow cells to increase production of reticulocytes and red blood cells, in that the mutein is N-glycosylated at Asn38 and Asn83 but not N-glycosylated at Asn24. Such muteins have improved pharmaceutical properties.

 
Web www.patentalert.com

< Method and system for molecular array scanner calibration

< Interactive system for presenting and eliminating substances

> Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains

> Tissue factor for influencing blood vessel formation
~ 00200